FEB 18, 2016
Aerie Pharmaceuticals announced positive 12-month interim safety results for Rhopressa, a once-daily eye drop for patients with glaucoma or ocular hypertension.
Rhopressa (netarsudil ophthalmic solution) 0.02% inhibits both Rho kinase and norepinephrine transporter and relaxes the trabecular meshwork to increase outflow and lower episcleral venous pressure.
In a previous study, the drop demonstrated non-inferiority to twice-daily timolol after 90 days of treatment. At 12 months, patients showed no new adverse events and no drug-related serious adverse events, while maintaining lower IOP.
"We are very pleased to see that Rhopressa continues to demonstrate a positive safety profile and, very importantly, consistent IOP lowering throughout the 12-month period. Our NDA filing remains on track for the third quarter of 2016," said Vicente Anido Jr., PhD, CEO at Aerie.